NEW YORK (GenomeWeb News) – DxS and Exosome Diagnostics said today that they will collaborate on developing blood-based companion diagnostics for cancer gene mutations, such as KRAS, BRAF, and EGFR.
Under the collaboration, the firms will team DxS' Scorpions real-time PCR Mutation Test Kits with Exosome's xOS technology for harvesting nucleic acids from blood exosomes. The firms hope to develop test kits that will measure gene mutations in blood and predict patient response to targeted therapies.
"Combining the ability to pull high-quality mutations from a simple blood draw with the unparalleled sensitivity and specificity of our Scorpion assays will provide our pharmaceutical and research customers with an ideal solution in personalized medicine," DxS CEO Stephen Little said in a statement.
Financial and further terms of the alliance were not disclosed.